Decreased miR-206 Expression in BRCA1 Wild-type Triple-negative Breast Cancer Cells After Concomitant Treatment with Gemcitabine and a Poly(ADP-ribose) Polymerase-1 Inhibitor

作者：Sasaki Akiko^*; Tsunoda Yuko; Tsuji Mayumi; Udaka Yuko; Oyamada Hideto; Tsuchiya Hiromichi; Oguchi Katsuji

来源：Anticancer Research, 2014, 34(9): 4893-4897.

• TNBC
• BRCA1
• PARP1
• miRNA
• breast cancer cells

No targeted-therapy has been established for triple-negative breast cancer accompanied by mutations in breast cancer susceptibility gene1 (BRCA1) mutation. In the present study, using BRCA1 wild-type cells (MDA-MB-231) and BRCA1-mutated cells (MDA-MB-436), we investigated miRNA expression and apoptosis on day 1 after addition of gemcitabine-alone and in combination with poly ADP-ribose polymerase-1 (PARP1) inhibitor. After drug treatment, there were significantly fewer apoptotic BRCA1 wild-type cells than BRCA1-mutated cells. Expression of miRNA-26a, -29b, -100, and -148a increased in BRCA1 wild-type cells exposed to gemcitabine-alone and in combination with the PARP1 inhibitor. The addition of PARP1 inhibitor reduced miR-206 expression in BRCA1 wild-type cells but increased it in BRCA1-mutated cells. It was suggested that miR-206 serves as a target molecule of PARP1 inhibitor combination therapy for BRCA1 wild-type triple-negative breast cancer cells.

• 出版日期2014-9